Company

Lys Therapeutics SAS

Lys Therapeutics develops antibody therapies for neurological diseases.

About

Lys Therapeutics is developing LYS241, a monoclonal antibody intended to address neuroinflammation and neurodegeneration. Founded in 2021, it is based in Lyon, France, with CEO Manuel Blanc, CFO Philippe Dujardin and Thibault Honegger among its founders. In September 2025, it secured a USD 5.00 mn grant from Bpifrance, Normandie Participations, France 2030 and Michael J. Fox Foundation.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in